It suggests that to avoid sending too many patients for routine bone scans, while also avoiding missing cases of metastasis, we can choose a PSA cut-off point of 20.85ng/mL and combine/support this with an ALP cut-off point of 44.0 IU/L in the subgroup with PSA values between 4.0 and 20.85 ng/mL (for all newly diagnosed, treatment-naïve, prostate cancer patients assessing care at our urology clinics). This evidence concerns the gene KLK3 and prostate carcinoma.